澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - fluticasone propionate, quantity: 20 mg; formoterol fumarate dihydrate, quantity: 0.8 mg - inhalation, pressurised - excipient ingredients: sodium cromoglycate; ethanol absolute; apaflurane - flutiform inhaler is indicated for the regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. this includes patients not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonist on an ?as required? basis.

马耳他 - 英文 - Medicines Authority

astrazeneca ab se-151 85, södertälje, sweden - budesonide, formoterol fumarate, dihydrate - pressurised inhalation, suspension - budesonide 80 µg formoterol fumarate dihydrate 2.25 µg - drugs for obstructive airway diseases

马耳他 - 英文 - Medicines Authority

astrazeneca ab se-151 85, södertälje, sweden - budesonide, formoterol fumarate, dihydrate - pressurised inhalation, suspension - budesonide 200 µg/spray formoterol fumarate dihydrate 6 µg/spray - drugs for obstructive airway diseases

马耳他 - 英文 - Medicines Authority

chiesi farmaceutici s.p.a via palermo 26/a, 43122 parma, italy - beclometasone dipropionate, formoterol fumarate, dihydrate - pressurised inhalation, solution - beclometasone dipropionate 100 µg formoterol fumarate dihydrate 6 µg - drugs for obstructive airway diseases

以色列 - 英文 - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - powder for inhalation - budesonide micronized 320 mcg/dose; formoterol fumarate 9 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler 320/9 mcg/dose is indicated in adults and adolescents, age 12 -17 for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor-agonist) is appropriate:-patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor-agonists.or- patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptoragonists.chronic obstructive pulmonary disease (copd)symbicort turbuhaler 320/9 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in i second (fev1) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy

马耳他 - 英文 - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - budesonide, formoterol fumarate, dihydrate - inhalation powder - budesonide 80 µg formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases

马耳他 - 英文 - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - budesonide, formoterol fumarate, dihydrate - prolonged-release tablet - budesonide 80 µg formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases

以色列 - 英文 - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.

以色列 - 英文 - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 125mcg/5mcg inhaler is indicated in adults and adolescents aged 12 years and above.

以色列 - 英文 - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.25 mg/dose; formoterol fumarate dihydrate 0.01 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 250mcg/10mcg inhaler is indicated in adults only.